Complete Genomics, a leading innovator in genomic sequencing, announced at the NextGen Omics & Spatial Biology Conference that it has partnered with BioTuring, developer of advanced bioinformatics ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Tempus AI leverages AI for treatment decisions and diagnostics, thriving in the booming healthcare AI market with strong ...

The use of biomarkers in medicine is transforming the way we detect diseases and develop treatments. Biomarkers are ...

Charles Schwab Investment Management Inc. lessened its stake in 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 17.2% in the ...

Technology Networks speaks to the method’s pioneer, Paul Hebert. Read on to learn about how the technique went from ...

Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

The substantial elimination of debt from the balance sheet, coupled with its transition towards profitability, positions the Company to leverage its strengthened financial position to accelerate ...

I was sorry to hear that 23andMe filed for Chapter 11 bankruptcy protection on Monday, but there would be a blizzard in Death ...

Discovery of novel NTD candidate genes and expansion of clinical implications of others, with identification of four genes – RMND5A, HNRNPC, FOXD4, and RBBP4 – having strong potential involvement in ...

Interventions involving bacteria or fungi could help to sequester greenhouse gases, create more sustainable products and ...

ELRIG, a not-for-profit, volunteer-led organisation for the drug discovery community, today announced the keynote speakers for Therapeutic Oligonucleotides 2025 taking place at the AstraZeneca R&D ...